November 18, 2026
Pfizer Inc. (NYSE: PFE) does not need artificial intelligence to discover its patent cliff. The calendar has that covered. What the drugmaker needs is for newer medicines to grow fast enough to replace sales lost as older drugs face…
SER-252 Advances as the Bullish Case Moves From Platform Promise to Clinical Execution
For a small biotechnology company, progress is best measured in patients dosed, safety reviews completed and the quality of the next clinical question. By those measures, Serina Therapeutics (NYSE American:…
The market’s most compelling bullish narratives rarely arrive wearing the same uniform. This week, they span a CEO buying millions of dollars of his own stock, an OLED display running at a downright impolite 720Hz, a telehealth company pursuing large institutional accounts,…
Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…
Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…
Wall Street has a new favorite subplot in the diabetes and obesity saga: a three-act story where Sanofi (SNY) shores up the autoimmune front, Modular Medical (MODD) quietly rewires insulin delivery, and the GLP‑1 heavyweights audition next‑gen obesity drugs on the ADA…
InMed Pharmaceuticals’ (NASDAQ: INM) planned merger with Mentari Therapeutics reads less like a struggling micro-cap pivot and more like a biotech coming‑of‑age story set against a trillion‑dollar headache: migraine. If the deal closes as outlined, a once‑overlooked cannabinoid platform could become the…
The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors.
FDA’s New Cast at the Top
The Food…
Family offices didn’t just come back to the deal table in April – they showed up with term sheets in one hand and stethoscopes in the other.
Healthcare Becomes the New Family Office Heirloom
Healthcare Becomes the New Family Office Heirloom
Family…
Health care may not have the meme-stock glamour of AI chips, but this spring the sector is quietly reminding investors why 'boring' can be beautiful. A trio of updates from Incyte (INCY), Pfizer (PFE) and Eupraxia Pharmaceuticals (NASDA: EPRX) is painting a…
